CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (Nasdaq: ALKS) today announced the completion of patient enrollment in a phase 1/2 clinical study of ALKS 29, the company’s undisclosed oral compound for the treatment of alcohol dependence. The multi-center, randomized, double-blind, placebo-controlled trial is designed to assess the safety and efficacy of ALKS 29 in approximately 150 subjects with alcohol dependence. Alkermes expects to provide top-line results from this study in the first half of calendar 2007.
